OncoMatch/Clinical Trials/NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Official title: A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Is NCT07308132 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments for lymphoma, non-hodgkin.
Treatment: JNJ-95566692 · JNJ-87801493 · loncastuximab tesirine · Lenalidomide · Rituximab · Gemcitabine · Oxaliplatin · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Polatuzumab vedotin — The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07308132 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages